CSL’s Alentis Deal Shows Biomarker Access Is the New Commercial Entry Point

Biotech is moving from biomarker discovery to biomarker control, where access to testing and patient selection determines who can commercialize targeted therapies.

Updated

What is this trend?

Biotech deals are increasingly built around securing biomarker testing, companion diagnostics, and patient-selection pathways that unlock commercial entry into targeted therapies.

  • Biomarker access is becoming the launch gate, not just a development tool.
  • Deals now value testing pathways and label-linked selection alongside the drug asset.
  • Rare disease and oncology are converging on biomarker-defined franchise strategies.
  • Control of diagnostics can shape trial speed, reimbursement, and market adoption.
  • Commercial power is shifting to whoever can identify and route the right patient.

What’s the latest?

CSL’s $355 million upfront deal for Alentis, with up to $1.2 billion in milestones and 55/45 profit sharing, is the clearest sign yet that biomarker-defined rare disease is being financed as a franchise-building strategy

Integrated discovery stacks, domestic IP control, and de-risked assets reshape biotech dealmaking

How it developed

  1. Platform Access Over Asset Buys, and Diagnostics AI as Oncology’s New Moat
    • Diagnostics and AI Are Becoming the Precision Oncology Moat

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Biotechnology

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.